Comparative evaluation of ofloxacin and metronidazole in the treatment of bacterial vaginosis.
OBJECTIVE
The epidemiology and etiology of bacterial vaginosis is poorly understood. Many antimicrobial agents have been studied and suggested as treatment alternatives for this infection. Fluoroquinolones have in vitro activity against some of the organisms associated with bacterial vaginosis and may provide another treatment option.


METHODS
Women who presented with symptomatic bacterial vaginosis were randomly assigned to receive either oral ofloxacin 300 mg twice a day or oral metronidazole 500 mg twice a day for seven days. Twenty-seven of the 31 patients who were enrolled in this double-blinded study were evaluable.


RESULTS
Fourteen women received ofloxacin. At follow-up, four had no residual symptoms, seven noted a reduction in symptoms, and three had no change in symptoms. Eight (57%) of the 14 women who received ofloxacin had secretions at follow-up that satisfied the criteria for the diagnosis of bacterial vaginosis. Thirteen women received metronidazole. Nine had no residual symptoms and four noted a reduction in symptoms. Eleven (85%) of the 13 women had normal vaginal secretions and two (15%) had secretions that were improved. None of the women who received metronidazole had secretions at follow-up that met the criteria for the diagnosis of bacterial vaginosis.


CONCLUSIONS
We conclude that ofloxacin is less effective than metronidazole in the treatment of bacterial vaginosis.
Covino
J M
JM
Department of Medicine, State University of New York Health Science Center at Brooklyn 11203.
Black
J R
JR
Cummings
M
M
Zwickl
B
B
McCormack
W M
WM
D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use*; D015242:Ofloxacin / Q000627:therapeutic use*; D016896:Treatment Outcome; D016585:Vaginosis, Bacterial / Q000188:drug therapy*
D008795:Metronidazole; D015242:Ofloxacin